Rebuttal from Authors re: Guido Dalbagni. Is Intravesical Bacillus Calmette-Guérin Better than Mitomycin for Intermediate-Risk Bladder Cancer? Eur Urol 2009;56:257-8

European Urology

Volumn 56, Issue 2, 2009, Pages 258-259

  Malmström, Per Uno ^a   Sylvester, Richard J ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN C; OFLOXACIN;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 67649441066     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.05.025     Document Type: Editorial

References (7)

1. Dalbagni G. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?. Eur Urol 56 (2009) 257-258
2. Bohle A., Jocham D., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
3. Bohle A., and Bock P.R. Intravesical bacillus Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-687
4. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
5. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
6. Colombel M., Saint F., Chopin D., Malavaud B., Nicolas L., and Rischmann P. The effect of ofloxacin on bacillus Calmette-Guérin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 176 (2006) 935-939
7. Leung A.S., Tran V., Wu Z., et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 15 (2008) 413